How Pfizer CEO Bourla's evening call brought Biohaven back into the M&A fold

Pfizer is in the process of buying migraine drug developer Biohaven Pharmaceuticals, upgrading their existing Nurtec ODT licensing agreement to a full-on acquisition. Starting with an April call from Pfizer CEO Albert Bourla, Ph.D., to Biohaven chief exec Vlad Coric, the two companies quickly came to terms on the buyout, a new Securities and Exchange Commission filing shows.